posaconazole
E556658
Posaconazole is a broad-spectrum triazole antifungal medication commonly used to prevent and treat serious invasive fungal infections, particularly in immunocompromised patients.
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
azole antifungal
ⓘ
broad-spectrum antifungal agent ⓘ pharmaceutical drug ⓘ triazole antifungal drug ⓘ |
| approvedBy | U.S. Food and Drug Administration NERFINISHED ⓘ |
| approvedIn |
European Union
NERFINISHED
ⓘ
United States NERFINISHED ⓘ |
| belongsToPharmacologicClass | systemic antifungals ⓘ |
| contraindicatedWith | certain CYP3A4 substrates that prolong QT interval ⓘ |
| developedBy |
Merck & Co.
NERFINISHED
ⓘ
Schering-Plough NERFINISHED ⓘ |
| discoveredIn | 1990s ⓘ |
| hasAdverseEffect |
QT interval prolongation
ⓘ
diarrhea ⓘ elevated liver enzymes ⓘ headache ⓘ nausea ⓘ vomiting ⓘ |
| hasATCCode | J02AC04 ⓘ |
| hasBioavailability | food-dependent ⓘ |
| hasChemicalClass | triazole ⓘ |
| hasDosageForm |
delayed-release oral tablet
ⓘ
intravenous solution ⓘ oral suspension ⓘ |
| hasHalfLife | approximately 25 to 35 hours ⓘ |
| hasPregnancyCategory | C (US, historical classification) ⓘ |
| hasRouteOfAdministration |
intravenous
ⓘ
oral ⓘ |
| hasSpectrumOfActivity |
Aspergillus species
ⓘ
Candida species ⓘ Mucorales NERFINISHED ⓘ Zygomycetes NERFINISHED ⓘ |
| hasTarget | fungal CYP51 (lanosterol 14α-demethylase) ⓘ |
| highlyProteinBound | true ⓘ |
| indicatedFor |
hematopoietic stem cell transplant recipients with graft-versus-host disease
ⓘ
immunocompromised patients at high risk of fungal infections ⓘ patients with hematologic malignancies with prolonged neutropenia ⓘ |
| isAdministeredTo |
adolescents
ⓘ
adults ⓘ |
| mechanismOfAction |
inhibition of ergosterol synthesis in fungal cell membranes
ⓘ
inhibition of fungal lanosterol 14α-demethylase ⓘ |
| metabolizedBy | UDP-glucuronosyltransferase UGT1A4 NERFINISHED ⓘ |
| usedFor |
prevention of invasive fungal infections
ⓘ
prophylaxis of Aspergillus infections ⓘ prophylaxis of Candida infections ⓘ treatment of invasive fungal infections ⓘ treatment of mucormycosis ⓘ treatment of oropharyngeal candidiasis ⓘ treatment of zygomycosis ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.